# Impact of cyclosporine A on the progression of ocular surface diseases: treatment efficacy and potential complications

## TL;DR

This study shows that 0.05% cyclosporine A eye drops reduce dry eye symptoms and improve tear film stability, though some patients experience mild side effects.

## Contribution

The study provides new insights into the efficacy and side effects of 0.05% cyclosporine A for dry eye treatment, focusing on both symptom relief and objective measures.

## Key findings

- Use of 0.05% cyclosporine A reduced discomfort and pain in dry eye patients.
- Objective measures like tear film breakup time and Schirmer test improved significantly.
- 20% of patients experienced moderate side effects like eye redness and pain during instillation.

## Abstract

Introduction. Eye diseases are widespread all over the world and, if left untreated, can lead to blindness.

Hypothesis. The use of 0.05% cyclosporine A (CsA) solution for the treatment of dry eye causes a decrease in discomfort and pain and improves objective measures such as tear film breakdown time, Schirmer test results and Oxford scale scores due to its anti-inflammatory and immunomodulatory properties that contribute to improved tear film stability and tear production.

Aim. This study aimed to investigate the impact of CsA on the progression of ocular surface diseases.

Methodology. An experiment was conducted on the basis of the FOCUS ophthalmology centre, Kazakhstan. A group of 100 individuals diagnosed with mild to severe dry eye illness were administered 0.05% CsA eye drops as part of the treatment protocol.

Results. The positive effect is explained by the anti-inflammatory and immunomodulatory effects of CsA. The study showed that the use of 0.05% CsA solution for the treatment of ocular surface disease led to a decrease in discomfort and pain, as well as an improvement in objective measures, including tear film breakdown time, Schirmer test results and Oxford scale scores. The visual analogue scale showed a significant reduction in symptoms, from 6.8 points at baseline to 3.7 points at day 60. In total, 20% of patients reported moderate side effects, such as pain during instillation and redness of the eye surface.

Conclusion. It is concluded that the use of these drops reduced pain, improved patient condition and enhanced indicators such as the visual analogue scale, tear film breakup time, Schirmer test and Oxford scale of corneal and conjunctival staining. This study differs from the previous ones in that it focuses on the efficacy of 0.05% CsA solution in the treatment of dry eye and also examines the spectrum and frequency of side effects, which is not sufficiently covered in previous studies.